Panagora Asset Management’s Acceleron Pharma XLRN Stock Holding History

Panagora Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-893	Closed	-$112K	–	2793
2021 Q2	$112K	Hold	893	–	–	﹤0.01%	1863
2021 Q1	$121K	Buy	+893	New	+$115K	﹤0.01%	1899
2020 Q4	–	Sell	-19,940	Closed	-$2.24M	–	3030
2020 Q3	$2.24M	Buy	+19,940	New	+$1.99M	0.01%	592
2015 Q4	–	Sell	-830	Closed	-$21K	–	2405
2015 Q3	$21K	Buy	830 +140	+20%	+$4.21K	﹤0.01%	2134
2015 Q2	$22K	Buy	+690	New	+$22.3K	﹤0.01%	2290
2015 Q1	–	Sell	-1,027	Closed	-$40K	–	2402
2014 Q4	$40K	Hold	1,027	–	–	﹤0.01%	2074
2014 Q3	$31K	Hold	1,027	–	–	﹤0.01%	2105
2014 Q2	$35K	Hold	1,027	–	–	﹤0.01%	2165
2014 Q1	$35K	Sell	1,027 -8,529	-89%	-$385K	﹤0.01%	2153
2013 Q4	$378K	Buy	+9,556	New	+$231K	﹤0.01%	1477

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Panagora Asset Management's XLRN Position: Q3 2021 in Review

Panagora Asset Management sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 893 shares — an estimated $112K sold.

Panagora Asset Management first reported a position in XLRN in Q4 2013 and held it in 10 quarters. The position peaked at $2.24M in Q3 2020. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Panagora Asset Management reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Panagora Asset Management sold 893 Acceleron Pharma shares in Q3 2021, an estimated $112K.
Panagora Asset Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 10 quarters.
Panagora Asset Management's Acceleron Pharma position peaked at $2.24M in Q3 2020.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.